Hedera Dx
Modern cancer care to the next billion people
31 employees · est. 2021 · Epalinges, Switzerland
EVIIVE AG
Unleash the full potential of liquid biopsies for the earliest disease prevention and personalized treatment guidance
2 employees · est. 2022 · Zurich, Switzerland
Hedera Dx is the older company (2021 vs 2022); Hedera Dx is the larger of the two.
Side-by-Side Comparison
| Metric | Hedera Dx | EVIIVE AG |
|---|---|---|
| Founded | ||
| Founded | 2021 older | 2022 |
| Headquarters | ||
| Headquarters | Epalinges, Switzerland | Zurich, Switzerland |
| Employees | ||
| Employees | 31 larger | 2 |
| Industry | ||
| Industry | Health Care | Biotechnology |
| Funding Stage | ||
| Funding Stage | Series A | Seed |
| Total Funding | ||
| Total Funding | $29.00M | $1.40M |
| Funding Rounds | ||
| Funding Rounds | 4 | 1 |
| Services | ||
| Services | Liquid Biopsy Solutions, Tumor Profiling Kits, Software & Analysis for Cancer Treatment, Implementation Programs for Hospital Labs, Clinical Studies and Trials | Not tracked yet |
| Target Customers | ||
| Target Customers | Hospital Laboratories, Oncologists, Healthcare Providers, Cancer Patients, Clinical Researchers | Not tracked yet |
| Taxonomy | ||
| Taxonomy | Modern Cancer Care, Liquid Biopsy, Next-Generation Sequencing, Non-Invasive Diagnosis, Timely Treatment Selection, Longitudinal Disease Monitoring, Clinic-Ready Solutions, Tumor Profiling, IVD Compliance, Privacy Infrastructure, Precision Medicine, CtDNA, Medical Device, Oncology, Innovative Work Environment | Oncology Biotech, Startup, Cancer Treatment, Preclinical-stage, Antibodies Development, Immune System Modulation, Cancer Cell Proliferation, Innovative Treatments, Cancer Patient Care, Immunotherapy, Biomedical Research, Immune Response, Cancer Therapy, Drug Development, Biopharmaceutical |
| Website | ||
| Website | hederadx.com | eviive.ch |
About Hedera Dx
Hedera Dx, founded in 2021, is a Swiss-based startup in the Health Care industry, poised to revolutionize cancer diagnostics. With the slogan, "Modern cancer care to the next billion people," the company offers innovative NGS-based liquid biopsies. These non-invasive tests not only facilitate early...
About EVIIVE AG
Ymmunobio is a pioneering preclinical-stage oncology biotech startup founded in 2021. Committed to revolutionizing cancer treatment, the company focuses on developing groundbreaking therapies for cancer patients. With a slogan of "Ymmunobio: Pioneering New Frontiers in Cancer Treatment," the startup...
We will tell you when either one moves
BounceWatch watches Hedera Dx and EVIIVE AG for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.
Funding, hiring, leadership and stack changes at Hedera Dx and EVIIVE AG — by email.
Frequently Asked Questions
Compare Hedera Dx with someone else
Start typing a company name or domain.
Related Comparisons
Compiled from the BounceWatch company index. We last looked at Hedera Dx on 13 Nov 2025, and EVIIVE AG on 11 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.